Compounds > adamantane
Page last updated: 2024-08-21

adamantane and Overweight

adamantane has been researched along with Overweight in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
D'Souza, K; Koska, J; Meyer, C; Osredkar, T; Reaven, PD; Sands, M; Sinha, S; Zhang, W1
Bhatt, DL; Braunwald, E; Davidson, J; Frederich, B; Hirshberg, B; Mosenzon, O; Ohman, P; Price, DL; Raz, I; Scirica, BM; Stahre, CI; Steg, PG; Udell, JA1
García-Ortega, YE; Gómez-Gaitán, EA; González-Ortiz, LJ; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA; Sánchez-Peña, MJ1
Del Prato, S; Foley, JE; Kothny, W; Kozlovski, P; Matthews, DR; Paldánius, PM; Stumvoll, M1

Trials

4 trial(s) available for adamantane and Overweight

ArticleYear
Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study.
    Diabetic medicine : a journal of the British Diabetic Association, 2019, Volume: 36, Issue:11

    Topics: Adamantane; Adipose Tissue; Adult; Aged; Blood Glucose; Cells, Cultured; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Endothelial Cells; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Obesity; Overweight; Postprandial Period; Treatment Outcome

2019
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:5

    Topics: Adamantane; Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Overweight; Prevalence; Risk Factors; Severity of Illness Index

2013
Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:7

    Topics: Adamantane; Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Male; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Vildagliptin

2013
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:10

    Topics: Adamantane; Adolescent; Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Metformin; Middle Aged; Nitriles; Obesity; Overweight; Pyrrolidines; Research Design; Vildagliptin; Young Adult

2014